EMA Authorised: Wezenla (ustekinumab) — Amgen Technology (Ireland) UC

View source ↗

Summary

Authorised approval of Wezenla (ustekinumab) by EMA for psoriasis, psoriatic arthritis, and Crohn's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• Wezenla (ustekinumab)

Snippet

Status: Authorised. Therapeutic area: Psoriasis;Arthritis, Psoriatic;Crohn Disease. MAH: Amgen Technology (Ireland) UC. Decision date: 25/06/2026